152 related articles for article (PubMed ID: 35305281)
1. Direct oral anticoagulants versus warfarin in patients with single antibody-positive anti-phospholipid syndrome.
Liu A; Rupani KV; Naymagon L
Eur J Haematol; 2022 Jul; 109(1):69-74. PubMed ID: 35305281
[TBL] [Abstract][Full Text] [Related]
2. Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome.
Williams B; Saseen JJ; Trujillo T; Palkimas S
J Thromb Thrombolysis; 2022 Jul; 54(1):67-73. PubMed ID: 34817786
[TBL] [Abstract][Full Text] [Related]
3. Comparing APLS and oranges: caution with the use of direct-acting oral anticoagulants (DOACs) instead of warfarin in the treatment of antiphospholipid syndrome (APLS).
Benger M; Vink J; Snell LB; Breen K
BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 30940667
[TBL] [Abstract][Full Text] [Related]
4. Choice of anticoagulation in patients with low risk antiphospholipid syndrome.
Bakow BR; Phung Q; Rabinovich D; Olszewski AJ; Reagan JL
J Thromb Thrombolysis; 2023 Jul; 56(1):121-127. PubMed ID: 37219825
[TBL] [Abstract][Full Text] [Related]
5. Direct oral anticoagulants versus warfarin in patients with antiphospholipid syndrome: A meta-analysis of randomized controlled trials.
Lee YH; Song GG
Lupus; 2022 Oct; 31(11):1335-1343. PubMed ID: 35968627
[TBL] [Abstract][Full Text] [Related]
6. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature.
Dufrost V; Risse J; Zuily S; Wahl D
Curr Rheumatol Rep; 2016 Dec; 18(12):74. PubMed ID: 27812956
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of the direct oral anticoagulants in non-triple positive antiphospholipid syndrome without prior arterial thromboembolism.
Kwan V; Kaplovitch E; Selby R; Abdulrehman J
J Thromb Thrombolysis; 2022 Apr; 53(3):690-696. PubMed ID: 34613576
[TBL] [Abstract][Full Text] [Related]
8. Use of direct oral anticoagulants in antiphospholipid syndrome.
Cohen H; Efthymiou M; Isenberg DA
J Thromb Haemost; 2018 Jun; 16(6):1028-1039. PubMed ID: 29624847
[TBL] [Abstract][Full Text] [Related]
9. Recurrent Thrombosis With Direct Oral Anticoagulants in Antiphospholipid Syndrome: A Systematic Literature Review and Meta-analysis.
Sanchez-Redondo J; Espinosa G; Varillas Delgado D; Cervera R
Clin Ther; 2019 Sep; 41(9):1839-1862. PubMed ID: 31405527
[TBL] [Abstract][Full Text] [Related]
10. Direct oral anticoagulants in antiphospholipid syndrome: Meta-analysis of randomized controlled trials.
Dufrost V; Wahl D; Zuily S
Autoimmun Rev; 2021 Jan; 20(1):102711. PubMed ID: 33197580
[TBL] [Abstract][Full Text] [Related]
11. Direct oral anticoagulants in antiphospholipid syndrome: a real life case series.
Betancur JF; Bonilla-Abadía F; Hormaza AA; Jaramillo FJ; Cañas CA; Tobón GJ
Lupus; 2016 May; 25(6):658-62. PubMed ID: 26743321
[TBL] [Abstract][Full Text] [Related]
12. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.
Malec K; Góralczyk T; Undas A
Thromb Res; 2017 Apr; 152():93-97. PubMed ID: 27989533
[TBL] [Abstract][Full Text] [Related]
13. Treatment of the antiphospholipid syndrome with direct oral anticoagulantsPosition statement of German societies.
Bauersachs R; Langer F; Kalka C; Konstantinides S; Klamroth R; Oldenburg J; Schellong S; Scholz U; Stücker M; Lindhoff-Last E
Vasa; 2019 Nov; 48(6):483-486. PubMed ID: 31621546
[No Abstract] [Full Text] [Related]
14. Direct oral anticoagulants in patients with antiphospholipid syndrome: a retrospective study in a real-life patient cohort.
Franke B; Luxembourg B; Heidinger K; Kemkes-Matthes B; Sachs UJ
Blood Coagul Fibrinolysis; 2022 Apr; 33(3):184-187. PubMed ID: 33587483
[TBL] [Abstract][Full Text] [Related]
15. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis.
Dufrost V; Risse J; Reshetnyak T; Satybaldyeva M; Du Y; Yan XX; Salta S; Gerotziafas G; Jing ZC; Elalamy I; Wahl D; Zuily S
Autoimmun Rev; 2018 Oct; 17(10):1011-1021. PubMed ID: 30103045
[TBL] [Abstract][Full Text] [Related]
16. Low recurrent thrombosis rates in single positive antiphospholipid syndrome regardless of type of anticoagulation.
Bakow BR; Yanek L; Crowther MA; Chaturvedi S
Thromb Res; 2024 May; 237():88-93. PubMed ID: 38569453
[TBL] [Abstract][Full Text] [Related]
17. Recurrent Thrombosis in Patients with Antiphospholipid Syndrome Receiving Newer Oral Anticoagulants: A Case Report and Review of Literature.
Joshi A; Hong J; Siva C
Clin Med Res; 2017 Jun; 15(1-2):41-44. PubMed ID: 28751467
[TBL] [Abstract][Full Text] [Related]
18. Direct-acting oral anticoagulants in antiphospholipid syndrome: A systematic review.
Girón-Ortega JA; Girón-González JA
Med Clin (Barc); 2023 Jul; 161(2):65-77. PubMed ID: 37105842
[TBL] [Abstract][Full Text] [Related]
19. Volume and Characteristics of Intracerebral Hemorrhage with Direct Oral Anticoagulants in Comparison with Warfarin
.
Adachi T; Hoshino H; Takagi M; Fujioka S;
Cerebrovasc Dis Extra; 2017; 7(1):62-71. PubMed ID: 28376486
[TBL] [Abstract][Full Text] [Related]
20. Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure.
Pengo V; Hoxha A; Andreoli L; Tincani A; Silvestri E; Prisco D; Fierro T; Gresele P; Cafolla A; De Micheli V; Ghirarduzzi A; Tosetto A; Falanga A; Martinelli I; Testa S; Barcellona D; Gerosa M; Denas G
J Thromb Haemost; 2021 Feb; 19(2):531-535. PubMed ID: 33128325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
